scholarly journals In vivo characterization and quantification of neurofibrillary tau PET radioligand [18F]MK-6240 in humans from Alzheimer’s disease dementia to young controls

2018 ◽  
Author(s):  
Tobey J Betthauser ◽  
Karly A Cody ◽  
Matthew D Zammit ◽  
Dhanabalan Murali ◽  
Alexander K Converse ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Optimal Timing ◽  
Reference Tissue ◽  
Time Activity ◽  
Imaging Characteristics ◽  
Tau Pet ◽  
Target Binding

ABSTRACTTau positron emission tomography (PET) imaging has potential for elucidating changes in the deposition of neuropathological tau aggregates that are occurring during the progression of Alzheimer’s disease (AD). This work investigatesin vivokinetics, quantification strategies and imaging characteristics of a novel tau PET radioligand [18F]MK-6240 in humans.MethodsFifty-one individuals ranging from cognitively normal young controls to persons with dementia underwent T1-weighted magnetic resonance imaging (MRI), and [11C]PiB and [18F]MK-6240 PET imaging. PET data were coregistered to the MRI and time-activity curves were extracted from regions of interest to assess [18F]MK-6240 kinetics. The pons and inferior cerebellum were investigated as potential reference regions. Reference tissue methods (Logan graphical analysis (LGA) and multilinear reference tissue method (MRTM2)) were investigated for quantification of [18F]MK-6240 distribution volume ratios (DVRs) in a subset of nineteen participants. Stability of DVR methods was evaluated using truncated scan durations. Standard uptake value ratio (SUVR) estimates were compared to DVR estimates to determine the optimal timing window for SUVR analysis. Parametric SUVR images were used to identify regions of potential off-target binding and to compare binding patterns with neurofibrillary tau staging established in neuropathology literature.ResultsStandard uptake values in the pons and the inferior cerebellum indicated consistent clearance across all 51 subjects. LGA and MRTM2 DVR estimates were similar, with LGA slightly underestimating DVR compared to MRTM2. DVR estimates remained stable when truncating the scan duration to 60 minutes. SUVR determined 70-90 minutes post-injection of [18F]MK-6240 indicated linearity near unity when compared to DVR estimates and minimized potential spill-in from uptake outside of the brain. [18F]MK-6240 binding patterns in target regions were consistent with neuropathological neurofibrillary tau staging. Off-target binding regions included the ethmoid sinus, clivus, meninges, substantia nigra, but not the basal ganglia or choroid plexus.Conclusions[18F]MK-6240 is a promising PET radioligand forin vivoimaging of neurofibrillary tau aggregates in AD with minimal off-target binding in the human brain.

[P3-338]: IN VIVO TAU PET IMAGING IN EARLY-ONSET ALZHEIMER's DISEASE AND LATE-ONSET ALZHEIMER's DISEASE

2017 ◽  
Vol 13 (7S_Part_22) ◽  
pp. P1083-P1083
Author(s):  
Young Noh ◽  
Han Kyu Na ◽  
Seongho Seo ◽  
Sang-Yoon Lee ◽  
Hye Jin Jeong ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Early Onset ◽  
Late Onset ◽  
Early Onset Alzheimer’S Disease ◽  
Tau Pet ◽  
Tau Pet Imaging

scholarly journals Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease

2021 ◽  
Vol 14 (2) ◽  
pp. 110
Author(s):  
Caitlin Jie ◽  
Valerie Treyer ◽  
Roger Schibli ◽  
Linjing Mu
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Second Generation ◽  
Tau Proteins ◽  
Tau Pathology ◽  
Pet Tracer ◽  
Positron Emission ◽  
Tau Pet ◽  
Target Binding

Tauvid has been approved by the U.S. Food and Drug Administration (FDA) in 2020 for positron emission tomography (PET) imaging of adult patients with cognitive impairments undergoing evaluation for Alzheimer’s disease (AD) based on tau pathology. Abnormal aggregation of tau proteins is one of the main pathologies present in AD and is receiving increasing attention as a diagnostic and therapeutic target. In this review, we summarised the production and quality control of Tauvid, its clinical application, pharmacology and pharmacokinetics, as well as its limitation due to off-target binding. Moreover, a brief overview on the second-generation of Tau PET tracers is provided. The approval of Tauvid marks a step forward in the field of AD research and opens up opportunities for second-generation tau tracers to advance tau PET imaging in the clinic.

The imaging features and clinical associations of a novel tau PET tracer - 18F-APN1607(18F-PM-PBB3) in Alzheimer’s disease

2020 ◽  
Author(s):  
Jung Lung Hsu ◽  
Kun-Ju Lin ◽  
Ing-Tsung Hsiao ◽  
Kuo-Lun Huang ◽  
Chi-Hung Liu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Standardized Uptake Value ◽  
Gender Effects ◽  
Imaging Features ◽  
Cognitive Changes ◽  
Posterior Cingulate ◽  
Tau Pet

Abstract Background: In vivo tau positron emission tomography (PET) imaging could help clarify the spatial distribution of tau deposition in Alzheimer’s disease (AD) and aid in the differential diagnosis of tauopathies. To date, there have been no in vivo 18 F-APN1607 tau PET studies in patients with AD.Methods: We applied tau tracer in twelve normal controls (NCs) and ten patients in the mild to moderate stage of probable AD. Detailed clinical information, cognitive measurements and disease severity were documented. Regional standardized uptake value ratios (SUVRs) from 18 F-AV-45 (florbetapir), 18 F-APN1607 PET images and regional gray matter (GM) atrophic ratios were calculated for further analysis.Results: Quantitative analyses showed significantly elevated SUVRs in the frontal, temporal, parietal, occipital lobes, anterior and posterior cingulate gyri, precuneus, and parahippocampal region (all ps < 0.01) with medium to large effect sizes (0.44 - 0.75). The SUVRs from 18 F-APN1607 PET imaging showed significant correlations with the ADAS-cog scores (all ps < 0.01) and strong correlation coefficients (R squared ranged from 0.54 to 0.68), even adjusted for age and gender effects. Finally, the SUVRs from 18 F-APN1607 PET imaging of the parahippocampal region showed rapid saturation as the ADAS-cog scores increased, and the SUVRs of the posterior cingulate gyrus and the temporal, frontal, parietal and occipital regions slowly increased. The combined SUVRs from 18 F-AV-45 PET, 18 F-APN1607 PET and regional GM atrophic ratio showed that uptake associated with the amyloid burden rapidly increased and reach a plateau, whereas uptake associated with tau depositions increased slowly and finally followed by regional GM atrophic ratios in most regions as the ADAS-cog scores increased. However, different regions exhibited various combinations of these patterns.Conclusions: Our findings suggest that the 18 F-APN1607 tau tracer showed a clear background without significant uptake in the basal ganglia or midbrain. Uptake of this tracer correlated well with cognitive changes and demonstrated the spatial pattern of amyloid, tau deposition and GM atrophy in the progression of AD. Thus, the regional base of dynamic biomarker changes was observed in the current study.Trial registration: registration number (NCT03625128), date of registration( August 10, 2018), retrospectively registered.

scholarly journals Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer’s disease dementia

2017 ◽  
Vol 23 (7) ◽  
pp. 1666-1673 ◽  
Author(s):  
K Chiotis ◽  
L Saint-Aubert ◽  
E Rodriguez-Vieitez ◽  
A Leuzy ◽  
O Almkvist ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Longitudinal Changes ◽  
Tau Pet ◽  
Alzheimer’S Disease Dementia ◽  
Tau Pet Imaging

O1-07-06: Hippocampal sparing and limbic predominant tau subtypes of Alzheimer's disease determined in vivo using [18F]-AV-1451 PET imaging

2015 ◽  
Vol 11 (7S_Part_3) ◽  
pp. P144-P145 ◽  
Author(s):  
Adam J. Schwarz ◽  
Sergey Shcherbinin ◽  
Bradley B. Miller ◽  
Peng Yu ◽  
Michael Navitsky ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Hippocampal Sparing

scholarly journals Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET

2020 ◽  
Vol 12 (524) ◽  
pp. eaau5732 ◽  
Author(s):  
Renaud La Joie ◽  
Adrienne V. Visani ◽  
Suzanne L. Baker ◽  
Jesse A. Brown ◽  
Viktoriya Bourakova ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Amyloid Pet ◽  
Specific Distribution ◽  
Positron Emission ◽  
Pet Radiotracers ◽  
Β Amyloid ◽  
Tau Pet ◽  
Prospective Longitudinal

β-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological hallmarks of Alzheimer’s disease (AD) and are thought to play crucial roles in a neurodegenerative cascade leading to dementia. Both lesions can now be visualized in vivo using positron emission tomography (PET) radiotracers, opening new opportunities to study disease mechanisms and improve patients’ diagnostic and prognostic evaluation. In a group of 32 patients at early symptomatic AD stages, we tested whether β-amyloid and tau-PET could predict subsequent brain atrophy measured using longitudinal magnetic resonance imaging acquired at the time of PET and 15 months later. Quantitative analyses showed that the global intensity of tau-PET, but not β-amyloid–PET, signal predicted the rate of subsequent atrophy, independent of baseline cortical thickness. Additional investigations demonstrated that the specific distribution of tau-PET signal was a strong indicator of the topography of future atrophy at the single patient level and that the relationship between baseline tau-PET and subsequent atrophy was particularly strong in younger patients. These data support disease models in which tau pathology is a major driver of local neurodegeneration and highlight the relevance of tau-PET as a precision medicine tool to help predict individual patient’s progression and design future clinical trials.

P4-315: TAU PET IMAGING WITH 18 F-PI2620 IN AGING AND ALZHEIMER'S DISEASE

2006 ◽  
Vol 14 (7S_Part_30) ◽  
pp. P1577-P1578
Author(s):  
Elizabeth C. Mormino ◽  
Ayesha Nadiadwala ◽  
Carmen Azevedo ◽  
Wanjia Guo ◽  
Jessa B. Castillo ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Tau Pet ◽  
Tau Pet Imaging

[IC-P-178]: HEAD-TO-HEAD IN VIVO COMPARISON OF TAU-SPECIFIC PET TRACERS IN ALZHEIMER's DISEASE: [11 C]THK5351 VERSUS [11 C]PBB3 PET IMAGING

2017 ◽  
Vol 13 (7S_Part_2) ◽  
pp. P133-P133 ◽  
Author(s):  
Konstantinos Chiotis ◽  
Per Stenkrona ◽  
Ove Almkvist ◽  
Ryosuke Arakawa ◽  
Akihiro Takano ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Pet Tracers

IC-P-156: Baseline amyloid PET imaging, longitudinal amyloid accumulation, and Tau PET imaging in preclinical Alzheimer's disease

2015 ◽  
Vol 11 (7S_Part_2) ◽  
pp. P105-P105
Author(s):  
Aaron P. Schultz ◽  
Elizabeth C. Mormino ◽  
Jasmeer P. Chhatwal ◽  
Molly LaPoint ◽  
Alex S. Dagley ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Amyloid Pet ◽  
Preclinical Alzheimer’S Disease ◽  
Amyloid Accumulation ◽  
Tau Pet ◽  
Tau Pet Imaging ◽  
Amyloid Pet Imaging

[P2-366]: HEAD-TO-HEAD IN VIVO COMPARISON OF TAU-SPECIFIC PET TRACERS IN ALZHEIMER's DISEASE: [11 C]THK5351 VERSUS [11 C]PBB3 PET IMAGING

2017 ◽  
Vol 13 (7S_Part_15) ◽  
pp. P765-P765 ◽  
Author(s):  
Konstantinos Chiotis ◽  
Per Stenkrona ◽  
Ove Almkvist ◽  
Ryosuke Arakawa ◽  
Akihiro Takano ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Pet Imaging ◽  
Pet Tracers
Sign in / Sign up

Export Citation Format

Share Document